echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > The Production Process of (E)-2-chloro-3-iMino-N,N-diMethylprop-1-en-1-aMine hydrochloride

    The Production Process of (E)-2-chloro-3-iMino-N,N-diMethylprop-1-en-1-aMine hydrochloride

    • Last Update: 2023-05-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The (E)-2-chloro-3-iMino-N,N-diMethylprop-1-en-1-aMine hydrochloride, also known as CARBAMATE-123, is an important chemical intermediate used in the production of various pharmaceuticals, agrochemicals, and other chemical products.
    The production process of CARBAMATE-123 involves several steps, including synthesis, purification, and characterization.
    In this article, we will discuss the production process of CARBAMATE-123 in detail.


    Synthesis of CARBAMATE-123
    The synthesis of CARBAMATE-123 involves several steps, including the preparation of the starting materials, the reaction steps, and the purification of the product.
    The starting materials for the synthesis of CARBAMATE-123 are methyl iodide and dimethylformamide, which are reacted in the presence of a solvent, such as toluene or dichloromethane, and a catalyst, such as Degussa P25 or Johnson Matthey catalyst.
    The reaction is carried out under controlled conditions, such as temperature and pressure, to produce the desired product.


    Purification of CARBAMATE-123
    After the synthesis of CARBAMATE-123, the product is typically purified to remove any impurities that may have been introduced during the synthesis process.
    The purification process typically involves several steps, including filtration, precipitation, and chromatography.
    Filtration is used to remove any solid impurities from the product, while precipitation is used to remove any insoluble impurities.
    Chromatography is used to separate the product from any other components that may be present in the mixture.


    Characterization of CARBAMATE-123
    After the purification process, the characterization of CARBAMATE-123 is performed to determine its chemical properties and molecular structure.
    The characterization process typically involves several techniques, including spectroscopy, spectrometry, and mass spectrometry.
    Spectroscopy is used to determine the molecular structure of CARBAMATE-123, while spectrometry is used to determine its elemental composition and molecular mass.
    Mass spectrometry is used to determine the molecular formula and molecular weight of CARBAMATE-123.


    Scale-up of CARBAMATE-123 Production
    After the synthesis, purification, and characterization of CARBAMATE-123 have been successfully completed, the next step is to scale up the production process to industrial levels.
    This involves the design and construction of large-scale production facilities, the selection of appropriate equipment and reagents, and the optimization of the production process for maximum efficiency and yield.


    Economic Considerations of CARBAMATE-123 Production
    The production of CARBAMATE-123 is a complex and multi-step process that requires specialized equipment and skilled personnel.
    The cost of production is also influenced by factors such as the cost of raw materials, energy costs, and labor costs.
    To ensure the economic viability of CARBAMATE-123 production, it is essential to carefully evaluate the costs and benefits of the production process and to optimize the production process for maximum efficiency and yield.


    Regulatory Considerations of CARBAMATE-123 Production
    The production of CARBAMATE-123 is subject to various regulatory requirements, depending on the intended use of the product.
    For example, if CARBAMATE-123 is intended for use in the pharmaceutical industry, it must be produced in accordance with good manufacturing practices (GMP) and meet the requirements of relevant regulatory agencies, such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
    The production process must also be designed and operated in


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.